May 19, 2025
TOPLINE: Fatigue, a common symptom immediately after a transient ischemic attack (TIA), persists up to a year after the event in 53.8% of patients, a new […]
May 16, 2025
The US Food and Drug Administration (FDA) has granted 510(k) clearance to the first blood test to aid in diagnosing Alzheimer’s disease (AD). The Lumipulse G […]
May 16, 2025
TOPLINE: Use of nucleoside reverse transcriptase inhibitors (NRTIs), but not other medications for HIV, was associated with a significantly reduced risk for Alzheimer’s disease (AD) in […]
May 16, 2025
An investigational oral selective orexin receptor 2 agonist (oveporexton, Takeda) demonstrated significantly improved measures of wakefulness, sleepiness, and cataplexy in a phase 2b study of adults […]
May 16, 2025
The largest study to date of magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy for essential tremor identified a target area within the ventral intermediate nucleus (VIM) that could […]
May 15, 2025
We’ve long known that migraine is an insidious disease. Patients with a variety of existing illnesses — atopic disorders, cardiovascular diseases, and sleep and/or psychiatric disorders […]
May 15, 2025
(Reuters) -The U.S. Food and Drug Administration has approved Amneal Pharmaceuticals’ self-administered migraine drug, giving way to a quick and more convenient treatment option for patients. […]
May 15, 2025
What has been described as a mysterious neurologic syndrome of unknown cause (NSUC) in the Canadian province of New Brunswick is a “perfect storm” of “misdiagnosis, […]
May 14, 2025
TOPLINE: A secondary analysis of the MR CLEAN-LATE trial found that penumbra volumes significantly modified the effectiveness of endovascular treatment (EVT) in patients with stroke in […]